HomeMarket NewsAcelyrin tanks, rival MoonLake rallies on failed clinical trial

Acelyrin tanks, rival MoonLake rallies on failed clinical trial

Actionable Trade Ideas

always free

Golden bull and bear on stock data chart background. Investing, stock exchange financial bearish and mullish market concept.


Acelyrin (NASDAQ:SLRN) inventory tanked in after-hours buying and selling Monday after the corporate mentioned its lead drug izokibep failed a mid-stage medical trial within the remedy of the pores and skin dysfunction hidradenitis suppurativa.

Shares of Acelyrin have been down 64% at $10 at round 5:30 p.m. ET. The

Swing Trading Ideas and Market Commentary

Need some new swing ideas? Get free weekly swing ideas and market commentary from Jonathan Bernstein here: Swing Trading.

Explore More

Weekly In-Depth Market Analysis and Actionable Trade Ideas

Get institutional-level analysis and trade ideas to take your trading to the next level, sign up for free and become apart of the community.